MT-601 dose 200 million cells
MRKR-22-601-02
Phase 1 small_molecule active
Quick answer
MT-601 dose 200 million cells for Pancreas Cancer is a Phase 1 program (small_molecule) at Marker Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Marker Therapeutics
- Indication
- Pancreas Cancer
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active